Mydcombi is a drug owned by Eyenovia Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 15, 2031. Details of Mydcombi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11398306 | Ophthalmic drug delivery |
Jul, 2031
(5 years from now) | Active |
| US10839960 | Ophthalmic drug delivery |
Jul, 2031
(5 years from now) | Active |
| US11839487 | Ophthalmic drug delivery |
Jul, 2031
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Mydcombi's patents.
Latest Legal Activities on Mydcombi's Patents
Given below is the list of recent legal activities going on the following patents of Mydcombi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 May, 2024 | US10839960 |
| Recordation of Patent eGrant | 12 Dec, 2023 | US11839487 |
| Patent Issue Date Used in PTA Calculation
Critical | 12 Dec, 2023 | US11839487 |
| Recordation of Patent Grant Mailed
Critical | 12 Dec, 2023 | US11839487 |
| Email Notification
Critical | 12 Dec, 2023 | US11839487 |
| Mail Patent eGrant Notification | 12 Dec, 2023 | US11839487 |
| Patent eGrant Notification | 12 Dec, 2023 | US11839487 |
| Email Notification
Critical | 23 Nov, 2023 | US11839487 |
| Issue Notification Mailed
Critical | 22 Nov, 2023 | US11839487 |
| Application Is Considered Ready for Issue
Critical | 02 Nov, 2023 | US11839487 |
FDA has granted several exclusivities to Mydcombi. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Mydcombi, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Mydcombi.
Exclusivity Information
Mydcombi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Mydcombi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2026 |
US patents provide insights into the exclusivity only within the United States, but
Mydcombi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Mydcombi's family patents as well as insights into
ongoing legal events
on those patents.
Mydcombi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Mydcombi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 15, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Mydcombi Generics:
There are no approved generic versions for Mydcombi as of now.
About Mydcombi
Mydcombi is a drug owned by Eyenovia Inc. It is used for dilating the pupils and reducing eye pressure. Mydcombi uses Phenylephrine Hydrochloride; Tropicamide as an active ingredient. Mydcombi was launched by Eyenovia in 2023.
Approval Date:
Mydcombi was approved by FDA for market use on 05 May, 2023.
Active Ingredient:
Mydcombi uses Phenylephrine Hydrochloride; Tropicamide as the active ingredient. Check out other Drugs and Companies using Phenylephrine Hydrochloride; Tropicamide ingredient
Treatment:
Mydcombi is used for dilating the pupils and reducing eye pressure.
Dosage:
Mydcombi is available in spray, metered form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2.5%;1% | SPRAY, METERED | Discontinued | OPHTHALMIC |